Research programme: protein kinase inhibitors - Asana BioSciences

Drug Profile

Research programme: protein kinase inhibitors - Asana BioSciences

Alternative Names: ASN-006; ASN-007; ASN007A

Latest Information Update: 01 May 2016

Price : $50

At a glance

  • Originator Asana BioSciences
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Focal adhesion protein-tyrosine kinase inhibitors; Mitogen-activated protein kinase inhibitors; Src-Family kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 30 May 2017 Asana BioSciences announces intention to file IND application to US FDA for ASN 007 in Cancer later in 2017
  • 16 Apr 2016 Pharmacodynamics and pharmacokinetics data from a preclinical trial in Cancer presented at the 107th Annual Meeting of the American Association for Cancer Research (AACR-2016)
  • 02 Nov 2015 Preclinical trials in Cancer in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top